Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Short-term Investments: 2024-2025

Historic Short-term Investments for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $175.3 million.

  • Zenas BioPharma's Short-term Investments rose 196887.64% to $175.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.3 million, marking a year-over-year increase of 196887.64%. This contributed to the annual value of $31.0 million for FY2024, which is N/A change from last year.
  • Per Zenas BioPharma's latest filing, its Short-term Investments stood at $175.3 million for Q3 2025, which was down 23.53% from $229.3 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Short-term Investments registered a high of $229.3 million during Q2 2025, and its lowest value of $86,000 during Q1 2024.
  • Moreover, its 2-year median value for Short-term Investments was $31.0 million (2024), whereas its average is $78.8 million.
  • Data for Zenas BioPharma's Short-term Investments shows a peak YoY soared of 260,437.50% (in 2025) over the last 5 years.
  • Zenas BioPharma's Short-term Investments (Quarterly) stood at $31.0 million in 2024, then surged by 196,887.64% to $175.3 million in 2025.
  • Its Short-term Investments was $175.3 million in Q3 2025, compared to $229.3 million in Q2 2025 and $115.8 million in Q1 2025.